Prostate Cell News Volume 12.17 | May 14 2021

May 12, 2022

2021-05-14 | PCN 12.17

Prostate Cell News by STEMCELL Technologies

Vol. 12.17 – 14 May, 2021

TOP STORY

ZIF‐Based Nanoparticles Combine X‐Ray‐Induced Nitrosative Stress with Autophagy Management for Hypoxic Prostate Cancer Therapy

In vitro and in vivo results indicated that zeolitic imidazole framework nanoparticles under X‐ray irradiation could effectively promote the apoptosis of hypoxic prostate cancer cells.
[Angewandte Chemie-International Edition]

Abstract

Webinar: The Promise of Organoid Medicine

PUBLICATIONSRanked by the impact factor of the journal

Androgen Signaling Uses a Writer and a Reader of ADP-Ribosylation to Regulate Protein Complex Assembly

Scientists showed that ADP-ribosylation regulated androgen receptor (AR) through a nuclear pathway mediated by poly(ADP-ribose) polymerase 7 (Parp7). They showed that Parp7 mono-ADP-ribosylated agonist-bound AR, and that ADP-ribosyl-cysteines within the N-terminal domain mediated recruitment of the E3 ligase Dtx3L/Parp9.
[Nature Communications]

Full Article

Tumor- and Osteoclast-Derived NRP2 in Prostate Cancer Bone Metastases

The authors reported that targeting neuropilin 2 (NRP2) in cancer cells could enhance taxane-based chemotherapy with a better therapeutic outcome in bone metastasis, implicating NRP2 as a promising therapeutic target.
[Bone Research]

Full Article

Functional Mapping of Androgen Receptor Enhancer Activity

To characterize the regulatory logic of androgen receptor (AR)-mediated transcription, researchers generated a locus-specific map of enhancer activity by functionally testing all common clinical AR binding sites with Self-Transcribing Active Regulatory Regions sequencing.
[Genome Biology]

Full Article

Cryopreservation of Human Cancers Conserves Tumor Heterogeneity for Single-Cell Multi-Omics Analysis

Using the Chromium 10X platform, scientists sequenced a total of ~ 120,000 cells from fresh and cryopreserved replicates across three primary breast cancers, two primary prostate cancers and a cutaneous melanoma.
[Genome Medicine]

Full Article

Targeting Epigenetic and Post-Transcriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth

Investigators conducted an in vitro chemical array screen and identified multiple small molecules that interacted with PSF. Several molecules inhibited RNA binding by PSF and decreased prostate cancer cell viability.
[Cancer Research]

Abstract

Proliferating Cell Nuclear Antigen Directly Interacts with Androgen Receptor and Enhances Androgen Receptor‑Mediated Signaling

Researchers suggested that androgen receptor (AR) was a proliferating cell nuclear antigen (PCNA) partner protein and interacted with PCNA via the PCNA‑interacting protein‑box.
[International Journal of Oncology]

Abstract

Low Amounts of Heavy Water Increase the Phase Separation Propensity of a Fragment of the Androgen Receptor Activation Domain

Scientists investigated how using D2O as co‐solvent in an aqueous buffer changes the phase equilibrium of a fragment of the activation domain of the androgen receptor, a transcription factor that plays a role in the development of the male phenotype and is a therapeutic target for castration resistant prostate cancer.
[Protein Science]

Abstract

Inverse Agonism at the Na/K‐ATPase Receptor Reverses EMT in Prostate Cancer Cells

The authors showed that the loss of cell surface expression of Na/K‐ATPase α1 induced epithelial–mesenchymal transition and promoted metastatic potential and tumor growth of prostate cancer by decreasing the expression of E‐cadherin and increasing c‐Myc expression via the activation of Src/FAK pathways.
[Prostate]

Abstract

Enjoy your weekend. Your cells will too. Reduce medium acidosis with mTeSR™ Plus.

REVIEWS

The Role of the p90 Ribosomal S6 Kinase Family in Prostate Cancer Progression and Therapy Resistance

Scientists review the roles of the p90 ribosomal S6 kinases in proliferation and motility, cell cycle control and therapy resistance in prostate cancer, highlighting the possible interplay between RSKs and Androgen Receptor in mediating disease progression.
[Oncogene]

Full Article

INDUSTRY AND POLICY NEWS

Avenda Health Granted FDA Breakthrough Device Designation for Technology to Treat Prostate Cancer

Breakthrough Device Designation was awarded to Avenda Health for a male “lumpectomy” product in development designed to treat prostate cancer in-office while preserving quality of life.
[Avenda Health (Business Wire, Inc.)]

Press Release

FEATURED EVENT

ZIF‐Based Nanoparticles Combine X‐Ray‐Induced Nitrosative Stress with Autophagy Management for Hypoxic Prostate Cancer Therapy

Androgen Signaling Uses a Writer and a Reader of ADP-Ribosylation to Regulate Protein Complex Assembly

Tumor- and Osteoclast-Derived NRP2 in Prostate Cancer Bone Metastases

Functional Mapping of Androgen Receptor Enhancer Activity

Cryopreservation of Human Cancers Conserves Tumor Heterogeneity for Single-Cell Multi-Omics Analysis

Targeting Epigenetic and Post-Transcriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth

Proliferating Cell Nuclear Antigen Directly Interacts with Androgen Receptor and Enhances Androgen Receptor‑Mediated Signaling

Low Amounts of Heavy Water Increase the Phase Separation Propensity of a Fragment of the Androgen Receptor Activation Domain

Inverse Agonism at the Na/K‐ATPase Receptor Reverses EMT in Prostate Cancer Cells

The Role of the p90 Ribosomal S6 Kinase Family in Prostate Cancer Progression and Therapy Resistance

Avenda Health Granted FDA Breakthrough Device Designation for Technology to Treat Prostate Cancer

EMBO Workshop: Long-Distance Cell-Cell Signaling in Development and Disease

> See All Events

Bioinformatics Officer – Prostate Cancer

Postdoctoral Research Fellow – mRNA Translation in Cancer

Postdoctoral Fellow – Prostate Cancer Biology

Director – Cancer Research

Postdoctoral Fellow – Prostate Cancer

> See All Jobs